Ozmosi | Acetylcholine chloride Drug Profile
Drug Profile
Using advanced filters...

Acetylcholine chloride

Alternative Names: acetylcholine chloride, acetylcholine, miochol-e, miochol, miochol e
Clinical Status: Inactive
Latest Update: 2026-10-29
Latest Update Note: Clinical Trial Update

Product Description

Acetylcholine Chloride is the chloride salt form of acetylcholine, a synthetic, quaternary amino alcohol with cholinergic properties. Acetylcholine chloride mimics the parasympathomimetic effect of the endogenous compound acetylcholine. Administered as an ophthalmic solution, this drug stimulates the cholinoceptors in the sphincter muscle of the iris, causing the pupil to constrict. (NCI05)

Mechanisms of Action: AChR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular, Transdermal, Oral, Topical, Intraocular, Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Canada | Chile | Colombia | Finland | France | Germany | Greece | Ireland | Italy | Japan | Jordan | Korea | Lebanon | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Peru | Portugal | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States | Venezuela

Approved Indications: None

Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Acetylcholine chloride

Countries in Clinic: Belgium, Sweden

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Healthy Volunteers|Myasthenia Gravis

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2024-515627-10-00

TLZ-C-001

P2

Not yet recruiting

Myasthenia Gravis

2026-11-30

2025-05-02

Treatments

2025-524564-38-00

CN0140003

P1

Not yet recruiting

Healthy Volunteers

2026-12-23

2018-004624-11

2018-004624-11

P2

Active, not recruiting

Healthy Volunteers

2021-03-13

2022-03-13

Treatments